touchRESPIRATORY caught up with Dr. Paulo Rodrigues Santos (University of Coimbra, Coimbra, Portugal) to discuss the challenges associated with the use of anti-PD-1 therapy in phase IIIB/IV non-small cell lung cancer, the cellular and plasmatic immunosuppressive factors that affect the outcome of anti-PD-1 therapy and the data supporting the strategies used to overcome these immunosuppressive factors.
The abstract ‘Cellular and plasmatic immune profile of anti-PD-1 therapy in phase IIIB/IV non-small cell lung cancer: relevance of immunosuppressive factors.‘ (Abstract number: PA1918) was presented at ERS 2022, 4–6 September, 2022.
Questions
- What are the current challenges associated with the use of anti-PD-1 therapy in phase IIIB/IV non-small cell lung cancer? (0:29)
- What cellular and plasmatic immunosuppressive factors are known to affect the outcome of anti-PD-1 therapy? (1:32)
- What strategies can be used to overcome these immunosuppressive factors? (2:13)
- What clinical evidence supports these strategies? (2:55)
- What questions remain unanswered and what future studies are planned? (3:30)
Disclosures: Paulo Rodrigues Santos has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
